Nkarta, Inc. (NKTX)
Nkarta develops engineered natural killer cell therapies for autoimmune diseases, led by its candidate NKX019. It last closed at $1.25 on Nov 17, up 3.31% on the day.
Key Stats
Fiscal 2025Not reported for this period.
From NKTX's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 5).
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on NKTX in the past 90 days. The average target is $12.00, with a high of $12.00 and a low of $12.00, compared with the last close of $1.25.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 2 | HC Wainwright & Co. | Assumed coverage | Buy | $12 |
| Aug 14 | Stifel | Maintained | Buy | $10 |
| Aug 11 | HC Wainwright & Co. | Maintained | Buy | $14 |
Technical Analysis
The stock is 25% below its 20 day and 70% below its 50 day average. It is 99% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot at $1.22, and the nearest resistance the Pivot R1 at $1.30.
| RSI (14) | 32.95 | Weak, oversold below 30 | Neutral |
| MACD | -0.23 | Below its signal line | Bearish |
| Stochastic | 15.2 | Near the bottom of its range | Oversold |
| ADX (14) | 45.3 | Strong downtrend | |
| Williams %R | -80.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -132.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −18.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.18 | Typical daily range, 14.4% of price |
| RSI (14) | 33.59 | Weak, oversold below 30 | Neutral |
| MACD | -0.30 | Below its signal line | Bearish |
| Stochastic | 8.1 | Near the bottom of its range | Oversold |
| ADX (14) | 20.4 | Weak trend | |
| Williams %R | -93.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -162.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −57.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.40 | Typical daily range, 32.3% of price |
What happened before
See how NKTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NKTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in NKTX in the last 90 days.
NKTX Institutional Ownership
Full report →- ●57 buying vs 64 selling
- ●Held by funds -0.3 pts
- ▼Funds holding -12
- ▼Superinvestors: 1 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 124 | 136 | −8.8% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 82.5% | 82.8% | −0.3 pts |
| New / increased | 7 / 50 | 26 / 52 | −26.9% |
| Reduced / sold out | 44 / 20 | 36 / 14 | +28.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NKTX is in one of them and how their past NKTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NKTX in an article yet. Here's the latest on the wider market.
About Nkarta
Nkarta is a clinical stage biopharmaceutical company based in South San Francisco, California. It develops engineered natural killer cell therapies made from cells donated by healthy people and produced in advance, so they can be given to patients without waiting for a custom batch. Its lead product candidate, NKX019, targets CD19 and is being studied in autoimmune diseases such as lupus nephritis and systemic sclerosis. The company aims its therapies at people living with these conditions.
- Headquarters
- South San Francisco, CA



